ARFGEF3

Across TCGA pan-cancer cohorts, ARFGEF3 mass-spec protein differs between tumor and matched normal tissue in 6 of 18 cancer types tested, making tumor–normal expression one of ARFGEF3’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where ARFGEF3 mass-spec protein is repressed in tumor relative to normal tissue. In most cancer types ARFGEF3 is over-expressed in tumor, although a few such as LSCC and PDAC show the opposite, repressed pattern.

LSCC, CCRCC, and PDAC are the cancer types where ARFGEF3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in ARFGEF3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Male	II,III,IV	−0.658	<.001	9	view →
CCRCC	All	II,III,IV	+0.390	<.001	9	view →
PDAC	Female	II,III,IV	−0.864	<.001	6	view →
HNSC	Male	II,III,IV	−0.825	<.001	6	view →
COAD	All	All	+0.195	<.001	6	view →
LUAD	All	All	+0.129	.019	4	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 6 strongest of 6 lineages.

ARFGEF3–LSCC

Open the LSCC breakdown →